Bioleaders Corporation
MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company's pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and… Read more
Bioleaders Corporation - Asset Resilience Ratio
Bioleaders Corporation (142760) has an Asset Resilience Ratio of 5.99% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Bioleaders Corporation's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Bioleaders Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩3.14 Billion | 5.99% |
| Total Liquid Assets | ₩3.14 Billion | 5.99% |
Asset Resilience Insights
- Limited Liquidity: Bioleaders Corporation maintains only 5.99% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Bioleaders Corporation Industry Peers by Asset Resilience Ratio
Compare Bioleaders Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Bioleaders Corporation (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Bioleaders Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 54.52% | ₩33.94 Billion | ₩62.25 Billion | +15.12pp |
| 2023-12-31 | 39.41% | ₩19.34 Billion | ₩49.07 Billion | +17.25pp |
| 2022-12-31 | 22.15% | ₩32.88 Billion | ₩148.42 Billion | -12.49pp |
| 2021-12-31 | 34.64% | ₩65.42 Billion | ₩188.85 Billion | +12.71pp |
| 2020-12-31 | 21.93% | ₩41.81 Billion | ₩190.69 Billion | -8.32pp |
| 2019-12-31 | 30.25% | ₩44.80 Billion | ₩148.11 Billion | +3.65pp |
| 2018-12-31 | 26.60% | ₩40.77 Billion | ₩153.29 Billion | -42.29pp |
| 2017-12-31 | 68.88% | ₩25.88 Billion | ₩37.58 Billion | +6.92pp |
| 2016-12-31 | 61.96% | ₩13.39 Billion | ₩21.61 Billion | -- |